Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sex-Based Disparities in Health Care Access and Utilization Among Patients With Atrial Fibrillation.

JAMA network open·2026

Same author

PR Interval Alternans and the Mystery of Inverse Decremental Conduction.

JACC. Case reports·2026

Same author

Patient health or corporate profits-Shouldn't the former come first?

The American journal of medicine·2026

Same author

Safety and Feasibility of Left Bundle Branch Area Pacing Following Transcatheter Tricuspid Valve Replacement.

JACC. Case reports·2026

Same author

Seemingly Reverse Wenckebach Phenomenon, Truly Inverse Decremental Conduction.

JACC. Case reports·2026

Same author

Practitioners and patients unite to resuscitate healthcare.

The American journal of medicine·2025

Search research articles

Related Experiment Video

Updated: Jan 31, 2026

Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies

Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies

Published on: July 19, 2007

Advances in Antiarrhythmic Drug Therapy: Potentials and Challenges.

Farah Olleik¹, Peter R Kowey²

¹Division of Cardiovascular Disease, Lankenau Medical Center, 100 E. Lancaster Avenue, Wynnewood, PA 19096, USA.

Cardiac Electrophysiology Clinics

|January 29, 2026

Summary

Antiarrhythmic drug innovation faces significant barriers. Future therapies require renewed investment to address the rising global prevalence of arrhythmias and improve patient outcomes.

Keywords:

Antiarrhythmic drugs Arrhythmia management Atrial fibrillation Device integration Hybrid therapy Proarrhythmia Regulatory barriers Ventricular tachycardia

More Related Videos

3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening

3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening

Published on: October 4, 2017

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies

Published on: September 13, 2024

Related Experiment Videos

Last Updated: Jan 31, 2026

Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies

Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies

Published on: July 19, 2007

3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening

3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening

Published on: October 4, 2017

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies

Published on: September 13, 2024

Area of Science:

Cardiology
Pharmacology
Translational Medicine

Background:

Antiarrhythmic drugs are crucial for managing atrial and ventricular arrhythmias.
Progress in antiarrhythmic drug development has been hindered by regulatory, scientific, clinical, and economic challenges.

Purpose of the Study:

To review the impediments to antiarrhythmic drug innovation.
To explore future therapeutic strategies for arrhythmias.

Main Methods:

Literature review of existing research and clinical data.
Analysis of barriers to drug development.
Exploration of emerging therapeutic approaches.

Main Results:

Identified key barriers slowing down antiarrhythmic drug innovation.
Highlighted novel delivery platforms, atrial-selective drugs, and hybrid approaches as future therapies.

Conclusions:

Addressing barriers and investing in patient-centered, mechanism-driven pharmacotherapy is essential.
Future antiarrhythmic drug development must complement procedural options to improve long-term outcomes for the growing number of arrhythmia patients.